PetIQ, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 28, 2024 at 04:09 pm EST
Share
PetIQ, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 219.93 million compared to USD 184.08 million a year ago. Net loss was USD 17.49 million compared to USD 6.84 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.24 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 0.24 a year ago.
For the full year, revenue was USD 1,101.96 million compared to USD 921.51 million a year ago. Net income was USD 2.13 million compared to net loss of USD 48.21 million a year ago. Basic earnings per share from continuing operations was USD 0.07 compared to basic loss per share from continuing operations of USD 1.65 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to diluted loss per share from continuing operations of USD 1.65 a year ago.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
